GRAL
HEALTHCAREGRAIL, LLC
AI Insight
What's Moving GRAL Today?
No stock-specific AI insight has been generated for GRAL yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$29.95$118.84
$62.37
Fundamentals
Market Cap$2.7B
P/E Ratio—
EPS$-10.30
Dividend Yield—
Dividend / Share—
ROE-16.1%
Profit Margin-253.2%
Debt / Equity—
Trading
Volume241K
Avg Volume (10D)—
Shares Outstanding42.9M
GRAL News
33 articles- GRAIL (NASDAQ: GRAL) reports 2026 shareholder votes on directors and auditorStock Titan·Jun 22, 2026
- A Blood Test That Screens for 50+ Cancers Just Moved Closer to Real-World Use. Here's What It Means for Grail Investors.The Motley Fool·Jun 21, 2026
- Levi & Korsinsky Notifies GRAIL, Inc. (GRAL) Investors - Lead Plaintiff Deadline on August 4, 2026ACCESS Newswire·Jun 20, 2026
- GRAL INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that GRAIL, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitBusiness Wire·Jun 19, 2026
- Deadline Alert: Grail, Inc. (GRAL) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud LawsuitThe National Law Review·Jun 18, 2026
- GRAL Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in GRAIL, Inc. Securities Lawsuit - Contact The Gross Law Firmlincolnjournal.com·Jun 12, 2026
- GRAL Shareholder Alert: Investors With Losses May Seek toGlobeNewswire·Jun 12, 2026
- SHAREHOLDER CLASS ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Grail (GRAL) Investors of Securities Class Action Deadline on August 4, 2026Eagle-Tribune·Jun 7, 2026
- SHAREHOLDER CLASS ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Grail (GRAL) Investors of Securities Class Action Deadline on August 4, 2026WBOC TV·Jun 7, 2026
- Honeywell Stock Is Likely to Reward Shareholders Following Quantinuum IPO, SplitBarchart·Jun 4, 2026
- CEO Ofman granted 31K RSUs in GRAIL (NASDAQ: GRAL) equity awardsStock Titan·Jun 4, 2026
- GRAIL (NASDAQ: GRAL) officer reports initial ownership of 165,229 sharesStock Titan·Jun 3, 2026
- A Look At GRAIL (GRAL) Valuation After A Sharp One Day Share Price DropYahoo Finance·Jun 2, 2026
- Grail Plummets On Mixed Results For Cancer-Screening Blood TestYahoo Finance·Jun 1, 2026
- GRAIL (GRAL) Is Up 6.7% After Mixed Galleri Trial Data At ASCO 2026 - Has The Bull Case Changed?Yahoo Finance·Jun 1, 2026
- GRAIL, Inc. (GRAL): One of the Best Stock Picks of Jeff BezosYahoo Finance·Jun 1, 2026
- Exchange-Traded Funds, Equity Futures Higher Pre-Bell Monday as AI Optimism Overshadows Middle East RisksYahoo Finance·Jun 1, 2026
- GRAIL’s Galleri Test Cuts Stage 4 Cancer Diagnoses in Study Despite Missed EndpointMarketbeat·Jun 1, 2026
- GRAIL Presents PATHFINDER 2 Results of More Than 35,000 Participants Showing the Galleri® Test Substantially Increased Cancer Detection With Robust Performance and Favorable Safety at 2026 ASCO Annual MeetingYahoo Finance·May 31, 2026
- GRAIL Reports Full Results From NHS-Galleri Trial Demonstrating Substantial Reduction in Stage IV Cancer Diagnoses at 2026 ASCO Annual MeetingYahoo Finance·May 30, 2026
- GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Yahoo Finance·May 27, 2026
- GRAIL to Present at the Goldman Sachs 47th Annual Global Healthcare ConferenceYahoo Finance·May 26, 2026
- GRAIL to Present at the 2026 Jefferies Global Healthcare ConferenceYahoo Finance·May 21, 2026
- GRAIL Says Galleri Demand Is Rising as NHS Talks, FDA Review Move AheadMarketbeat·May 17, 2026
- How The GRAIL (GRAL) Narrative Is Shifting After NHS Galleri Results And Reimbursement QuestionsYahoo Finance·May 8, 2026
- [10-Q] GRAIL, Inc. Quarterly Earnings ReportStock Titan·May 8, 2026
- GRAIL Q1 Earnings Call HighlightsMarketbeat·May 6, 2026
- GRAIL Reports First Quarter 2026 Financial ResultsYahoo Finance·May 5, 2026
- GRAIL to Present at the BofA Securities 2026 Health Care ConferenceYahoo Finance·Apr 30, 2026
- Will Ultragenyx (RARE) Report Negative Q1 Earnings? What You Should KnowYahoo Finance·Apr 28, 2026
- GRAIL to Announce First Quarter 2026 Financial ResultsYahoo Finance·Apr 22, 2026
- GRAIL to Present New Data From NHS-Galleri and PATHFINDER 2 at 2026 ASCO Annual MeetingYahoo Finance·Apr 21, 2026
- Here's Why Grail Stock Soared Higher This WeekThe Motley Fool·Mar 26, 2026
All 33 articles loaded
Price Data
Open$60.00
Previous Close$62.10
Day High$63.82
Day Low$60.00
52 Week High$118.84
52 Week Low$29.95
52-Week Range
$29.95$118.84
$62.37
Fundamentals
Market Cap$2.7B
P/E Ratio—
EPS$-10.30
Dividend Yield—
Dividend / Share—
ROE-16.1%
Profit Margin-253.2%
Debt / Equity—
Trading
Volume241K
Avg Volume (10D)—
Shares Outstanding42.9M
About GRAIL, LLC
GRAIL, LLC is a leading biotechnology firm specializing in advanced cancer diagnostics, particularly through its innovative blood tests designed for multi-cancer early detection (MCED). Utilizing proprietary genomic technologies, the company is committed to enhancing precision medicine by offering vital insights for proactive health management and improving patient outcomes. GRAIL is poised to address critical gaps in cancer screening and diagnostics, establishing itself as a pivotal entity in the dynamic oncology landscape, with the potential to significantly impact the future of cancer care.
HEALTHCAREDIAGNOSTICS & RESEARCH
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICDIAGNOSTICS & RESEARCH
CIK—
Composite FIGI—
Share Class FIGI—